Imagine a 'Nespresso machine' for skin biopsies. Instead of sending a sample to a distant lab and waiting days for a subjective human opinion, a doctor puts the sample in a small disc and presses a button. In under 90 minutes, the machine analyzes the molecules to give a precise, objective answer. It removes the guesswork from diagnosing skin conditions.
Conventional skin diagnostics are subjective and imprecise, leading to up to 50% misdiagnosis. This results in harmful therapies, unnecessary hospitalizations, and increased healthcare costs.
A two-part automated platform: the LabDisk (a microchannel cartridge for sample processing) and the LabDisk-Analyzer (a portable unit for signal detection and results).
If you are a private practice dealing with slow lab turnaround times and subjective results — this project developed a portable analyzer that delivers objective results within 45-90 min. This allows for immediate treatment decisions during the patient visit.
If you are a diagnostic lab dealing with the high cost and time of manual molecular testing — this project developed a fully automated platform that can detect 40 or more different molecular targets simultaneously. This increases throughput and reduces manual labor errors.
If you are a hospital administrator dealing with high costs caused by up to 50% misdiagnosed skin cases — this project developed a cost-efficient automated platform. This reduces unnecessary hospitalizations and harmful therapies caused by imprecise diagnostics.
The project data does not specify the unit price of the device, but describes the platform as a 'cost-efficient' solution designed to reduce overall healthcare costs.
Yes, the system is designed as a fully automated platform consisting of a microchannel cartridge (LabDisk) and a portable analyzer, allowing it to be run anywhere and at any time.
Based on available project data, the technology is developed by Dermagnostix GmbH, which has successfully completed a Series A funding round of 5.4 M Euro to support its commercialization.
The automated process delivers objective results within 45-90 minutes.
It replaces manual molecular tests with a 'plug-and-play' workflow: the user inserts a sample (paraffin-embedded tissue, biopsy, or tapestrip) into the disk and presses start.
The project is led by a single SME, Dermagnostix GmbH from Germany. This 100% industry-led structure indicates a strong focus on commercialization rather than academic research, supported by significant private capital (5.4 M Euro Series A) and an active pursuit of Series B funding.
Contact Dermagnostix GmbH in Germany regarding their LabDisk-Analyzer platform.
Contact us to explore licensing or partnership opportunities with this automated diagnostic platform.
